Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Advanced Hepatocellular Carcinoma
Clinical trial register · China

Advanced Hepatocellular Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 4 Shanghai 3 Hangzhou 3 Shenzhen 2 Fuzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing4 Shanghai3 Hangzhou3 Shenzhen2 Fuzhou1
All 10 locations
Target enrolment
to

Advanced Hepatocellular Carcinoma trials in China

18 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Zhejiang University
Phase 1
12
Hangzhou
2025-01-10
Recruiting
Shanghai Changzheng Hospital
Early Phase 1
37
Shanghai
2024-10-12
Recruiting
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
NCT06644430Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
Sun Yat-sen University
Observational
470
Beijing
2024-10-04
Recruiting
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
NCT06609863Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
Sun Yat-sen University
Not applicable
27
Beijing
2024-10-01
Recruiting
Xu Yong, MD
Phase 2
30
Shenzhen
2024-09-03
Recruiting
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
NCT06550921Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation, Anti-PD1 Antibody
Sun Yat-sen University
Not applicable
60
Beijing
2024-08-01
Recruiting
Zhejiang University
Phase 1
15
Hangzhou
2024-07-01
Recruiting
Zhiyong Huang
Phase 1
50
Wuhan
2024-06-01
Recruiting
Wen Tianfu
Phase 3
196
Chengdu
2024-05-10
Recruiting
Fujian Medical University
Phase 2
57
Fuzhou
2024-04-12
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2024-03-20
Not yet open
Sun Yat-sen University
Phase 3
136
Guangzhou
2023-03
Recruiting
Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
NCT05620706Advanced Hepatocellular Carcinoma
Shenzhen University General Hospital
Not applicable
20
Shenzhen
2022-11-01
Recruiting
Fudan University
Phase 2
25
Shanghai
2021-09-26
Active, closed
Zhejiang University
Phase 1
21
Hangzhou
2021-03-10
Recruiting
Sun Yat-sen University
Observational
240
Beijing
2021-01-01
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/condition/advanced-hepatocellular-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies listing the condition Advanced Hepatocellular Carcinoma.

How many Advanced Hepatocellular Carcinoma trials are recruiting in China?

16 of the 18 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Hepatocellular Carcinoma), 18 studies
PhaseStudiesRecruitingShare
Phase 25527.8%
Phase 14322.2%
Not applicable3316.7%
Phase 33216.7%
Observational2211.1%
Early Phase 1115.6%

Most active sponsors

Lead sponsors with the most studies (Advanced Hepatocellular Carcinoma)
Lead sponsorStudiesRecruiting
Sun Yat-sen University54
Zhejiang University32
Fudan University11
Fujian Medical University11
Shanghai Changzheng Hospital11
Shenzhen University General Hospital11
Sichuan Baili Pharmaceutical Co., Ltd.11
Suzhou Suncadia Biopharmaceuticals Co., Ltd.11
Tianjin Medical University Cancer Institute and Hospital11
Wen Tianfu11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.